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BAD-LAMP controls TLR9 trafﬁcking and signalling
in human plasmacytoid dendritic cells
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Toll-like receptors (TLR) are essential components of the innate immune system. Several
accessory proteins, such as UNC93B1, are required for transport and activation of nucleic acid
sensing Toll-like receptors in endosomes. Here, we show that BAD-LAMP (LAMP5)
controls TLR9 trafﬁcking to LAMP1+ late endosomes in human plasmacytoid dendritic cells
(pDC), leading to NF-κB activation and TNF production upon DNA detection. An inducible
VAMP3+/LAMP2+/LAMP1− endolysosome compartment exists in pDCs from which TLR9
activation triggers type I interferon expression. BAD-LAMP-silencing enhances TLR9
retention in this compartment and consequent downstream signalling events. Conversely,
sustained BAD-LAMP expression in pDCs contributes to their lack of type I interferon
production after exposure to a TGF-β-positive microenvironment or isolation from human
breast tumours. Hence, BAD-LAMP limits interferon expression in pDCs indirectly, by
promoting TLR9 sorting to late endosome compartments at steady state and in response to
immunomodulatory cues.
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Members of the Toll-like receptor (TLR) family are innateimmune sensors for pathogen-associated molecularpatterns, ranging from bacterial cell wall components
to viral and bacterial nucleic acids1. TLRs use a set of
signalling adaptors to induce a transcriptional response, which
leads to pro-inﬂammatory cytokines and type I interferon (IFN)
production2, 3. TLRs are divided into two subgroups according to
extracellular or intracellular localisation and respective ligands4.
Intracellular TLRs, such as TLR3, TLR7 and TLR9, recognise
nucleic acids and need to be proteolytically activated in endo-
somes to signal5–7. For instance, cleaved TLR9 is activated by
unmethylated cytosine-phosphate-guanine dinucleotides (CpG)
DNA motifs that are frequently present in microbes but are rare
in mammalian cells8, 9. Hence, in physiological conditions, TLR9
is a sensor of infection10; however, in mice and in patients with
lupus-like symptoms, TLR9 can be activated by immune
complexes formed with self DNA11. Tightly controlled TLR9
transport and activation seem, therefore, to be particularly
important to prevent autoimmunity and discriminate self from
non-self DNA12. Subcellular distribution of TLRs correlates well
with membrane compartments, in which ligands are found and
can drive activation of different signalling cascades13. Endocytic
TLRs require an additional accessory protein, the uncoordinated
93 homologue B1 (UNC93B1) to leave the endoplasmic reticulum
(ER) and reach endosomes to be activated14–17. However,
the mechanisms controlling the initiation of UNC93B1–TLR
complex transport from the ER to endosomes are not clear. Upon
entry of TLRs in the endocytic pathway, additional sorting to
speciﬁc signalling compartments, from which IRFs or NF-κB
can be activated respectively, is required. Regulated access to
IRF-signalling endosomes (SE) or NF-κB-SEs, is thus necessary to
coordinate IFNs and pro-inﬂammatory cytokine production18–20.
Supporting the importance of this sorting step, DCs and
macrophages isolated from adaptor protein 3 (AP-3)-deﬁcient
mice21, or from patients with Hermansky–Pudlak syndrome
type 2 (HPS2)22, are deﬁcient in late endosomal transport and
consecutive type I IFN production. However, these deﬁciencies
do not, or only moderately, affect pro-inﬂammatory cytokines
expression in response to TLR9 stimulation21.
pDCs have a unique capacity to produce a large amount of IFN
in response to nucleic acids3 and display specialized molecular
features that control IRF7 activation directly downstream of
TLR7 and TLR9. In addition to granulin23, which favors CpG
ODN capture, other molecules, including the solute carrier
protein superfamily member Slc15a4 or the biogenesis of
lysosome-related organelles complexes (BLOC) proteins are
required by pDCs, but not by conventional DCs to respond to
DNA24, 25. pDCs seem, therefore, to have developed a speciﬁc
regulation of their endocytic compartments, that controls TLR
access to different endosome subsets to achieve a coordinated and
commensurate DNA detection response to potential threats.
The brain and DC-associated LAMP-like molecule (BAD-
LAMP/LAMP5), which shares sequence and structural homology
with the canonical lysosomal-associated membrane proteins
LAMP1 and LAMP2, is expressed in the nervous tissues of
most metazoan species26, 27. BAD-LAMP is also expressed by
non-activated human pDCs and blastic pDCs neoplasms
(BPDCN) from leukaemic patients, enabling rapid identiﬁcation
in tissues and blood28.
Here, we show using human primary pDCs and the BPDCN-
derived CAL-1 cell line that BAD-LAMP controls the sorting of
TLR9 in different endosome subsets and favors pro-inﬂammatory
cytokine production. Upon CpG detection, BAD-LAMP is
transported with TLR9 to the IRF7-SE, where it promotes further
TLR9 sorting to LAMP1+ NF-κB-SE. Inhibition of BAD-LAMP
activity therefore promotes TLR9 retention in IRF7-SE and leads
to increased IFN expression. Confocal microscopy analysis of
IRF7-SE shows that this SE is a CpG-inducible endosomal
hybrid/intermediate compartment containing both the sorting
endosomes-associated SNARE protein vesicle-associated
membrane protein 3 (VAMP3) and LAMP2, but not its close
relative LAMP1. We further show that pDCs exposure to
immunosuppressive cytokines or tumour supernatants prevents
the down-modulation of BAD-LAMP, which is normally rapid
after activation by CpG, and consequently limits type I IFN
production. The sustained BAD-LAMP expression in breast
tumour-associated pDCs is therefore likely to contribute to the
lack of IFN-α production, a dysfunctional phenotype generally
associated with immune tolerance and aggressive cancer29, 30.
Results
BAD-LAMP is downregulated by type I IFN in human pDC.
Previous studies established that the BPDCN-derived CAL-1 cells
share many of phenotypic and functional properties of freshly
isolated human CD123 + /BDCA4 + pDCs31, 32. BAD-LAMP
expression was monitored both in isolated primary pDCs from
blood and CAL-1 cells using intracellular ﬂow cytometry
(Fig. 1a). BAD-LAMP, TLR9 and UNC93B1 were found
expressed at high levels in both cell types. After 24 h of CpG-A
activation a strong decrease in both BAD-LAMP and TLR9
expression was observed (Fig. 1a). BAD-LAMP disappearance
was associated with a reduction in mRNA levels (Fig. 1b),
initiated 3 h after CpG stimulation and concomitantly to the
type-I IFN production peak observed in both cell types (Fig. 1c).
On the basis of the IFN-α and TNF mRNA expression, we could
recapitulate the existence of a bimodal activation of
TLR9 signalling by CpG-A with ﬁrst an IRF7-dependent phase
(red), followed by an NF-κB-dependent phase (blue; Figs. 1c, 2)33.
Examination of the signalling pathways downstream of TLR9 by
immunoblots (Fig. 1d) conﬁrmed that in CAL-1, the TBK1/IRF7
cascade leading to type-I IFN transcription, was activated by
CpG-A within the ﬁrst hours of treatment, while the peak of
NF-κB (p65) phosphorylation appeared after 3 h of treatment.
Interestingly, BAD-LAMP down-modulation was observed upon
stimulation with all types of CpG ODN28. However, with CpG-A,
it was initiated at the transition step between the two signalling
phases (Fig. 1b, d, e), concomitantly with IFN receptor (IFNAR)
signalling, monitored by STAT1 phosphorylation (Fig. 1d).
Exogenous IFN-α treatment and IFNAR inhibition with antag-
onistic antibodies further demonstrated that BAD-LAMP dis-
appearance is caused by IFNAR stimulation (Supplementary
Fig. 1). An observation conﬁrmed by using the cysteine protease
inhibitor ZA-FA-FMK that prevents TLR9 processing7 and
consequently IFN-α induction (Supplementary Fig. 2A). Upon
CpG stimulation, BAD-LAMP is rapidly downregulated both at
mRNA and protein levels28 (Fig. 1c–e). While IFNAR signalling
was strongly correlated with transcriptional shut-down (Supple-
mentary Fig. 1B), we further investigated whether BAD-LAMP
proteolysis was due to lysosomal targeting as expected from a
bona-ﬁde LAMP family member. Both Baﬁlomycin A1 and
Chloroquine, two drugs neutralising endosomal pH, prevented
BAD-LAMP protein degradation (Supplementary Fig. 2B, C) and
promoted its accumulation in Lamp1 + compartment (Supple-
mentary Fig. 2D), conﬁrming that BAD-LAMP is normally tar-
geted and rapidly degraded in late endosomes/lysosomes.
However, upon TLR9 or IFNAR triggering, BAD-LAMP mRNA
is rapidly downregulated causing the protein disappearance
within few hours of pDC stimulation.
BAD-LAMP co-localises with UNC93B1 and TLR9 during
activation. BAD-LAMP downregulation upon TLR9 activation
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Fig. 1 BAD-LAMP is down-modulated after IRF7 activation. a (left) Flow cytometry analysis of CAL-1 cells (top) and freshly isolated pDCs (bottom) from
healthy donors stained for both extracellular (CD123 and BADCA4) and intracellular (TLR9 and BAD-LAMP) pDCs markers. (right) Flow cytometry
histogram plots of intracellular staining for BAD-LAMP, TLR9 and UNC93B1 in both CAL-1 (left) and freshly isolated pDCs (right) at steady state (black line)
and after 24 h of CpG-A stimulation (dashed line). Full grey histograms represent isotype controls staining. Data are representative of a minimum of three
independent experiments. b CAL-1 (black line) and freshly isolated pDCs (dashed line) were treated with CpG-A for indicated times. BAD-LAMP mRNA
levels were measured by RT-qPCR. Raw data have been normalised to housekeeping gene (GAPDH) and graphics represent fold change± s.d. compared to
non-stimulated cells from a minimum of three independent experiments. c IFNα2 (red) and TNF (blue) mRNA level from CAL-1 (left) and freshly isolated
pDCs (right) were measured by RT-qPCR. Raw data have been normalised to housekeeping gene (GAPDH) and graphics represent fold change± s.d.
compared to non-stimulated cells from a minimum of three independent experiments. d (top) CAL-1 cells were treated with CpG-A for indicated times prior
lysis and sodium dodecyl sulphate–polyacrylamide gel electrophoresis treatment. Expression of BAD-LAMP, TBK1, IRF7, STAT1, the p65 NF-κB subunit,
Ribosomal S6 and their phosphorylated forms were detected by immunoblot. β-actin is shown as loading control. d (bottom) Quantiﬁcation of IRF7 (red)
and p65 (blue) phosphorylation levels. Graphics represents data normalised to total form levels for each protein± s.d. from three independent experiments.
e (bottom) Quantiﬁcation of BAD-LAMP protein expression by Image J pixel quantiﬁcation. Graphics represents data normalised β-actin levels± s.d. from
three independent experiments. The bimodal regulation of TLR9 signalling is represented with a shading red rectangle for its IRF7-dependent phase and blue
for its NF-κB-dependent phase
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lead us to investigate BAD-LAMP, TLR9 and its signalling adaptor
MYD88 subcellular distribution by performing multicolour
confocal microscopy on both freshly isolated primary blood pDC
and CAL-1 at key time points of activation by CpG-A. At steady
state, BAD-LAMP, TLR9 and MYD88 were poorly co-distributed
(Fig. 3a). After 1 h of stimulation, the degree of co-localisation
between the three proteins became maximal (white arrows;
Pearson’s coefﬁcient Fig. 3a right). With time, BAD-LAMP
and TLR9 co-localisation steadily decreased, until BAD-LAMP
down-regulation was fully effective (6 h). As expected from IRF7
phosphorylation and cytokines expression levels (Fig. 1), TLR9
and MYD88 co-localisation reached its peak at 1 h after CpG
stimulation and was maintained for at least 5 h (Fig. 3a, Pearson’s
coefﬁcient). The antibody used to detect endogenous TLR9 seems
incapable to recognise the pre-Golgi form of TLR9 and mostly
allows visualisation of functional TLR9 in endosomes6, thus
potentially impairing our capacity to reveal any pre-existing
interactions with ER-resident TLR9 prior processing and pDC
activation. Nevertheless, the co-distribution of BAD-LAMP with
processed TLR9 and MYD88 after 1 and 3 h of activation,
was conﬁrmed using voxel gating imaging to reveal areas of triple
co-localisation with BAD-LAMP (Fig. 3b), suggesting that the
three molecules reside in close vicinity in the same endocytic
compartment at a key moment of TLR9 signalling.
We increased the resolution of our analysis by performing
confocal imaging using in situ Proximity Ligation Assay (iPLA)34
to quantify the proximity of BAD-LAMP with UNC93B1 and
TLR9 (Figs. 3c d). As anticipated from BAD-LAMP and
UNC93B1 co-localisation in HeLa cells28, BAD-LAMP and
UNC93B1 were found in close proximity (⩽40 nm) in
non-activated pDCs. This proximity was rapidly lost upon CpG
stimulation and replaced by a strong co-localisation between
BAD-LAMP and TLR9, observed concomitantly with MYD88
recruitment after 1 h of activation (Figs 3d e). However, TLR9
vicinity with BAD-LAMP faded with time, while its association
with MYD88 persisted (Fig. 3e). These observations suggest that
BAD-LAMP and UNC93B1 co-exist in the ER of human pDC at
steady state, and that upon activation, this interaction is
substituted by a novel and exclusive relationship between
BAD-LAMP and functional TLR9 molecules in signalling
endosomes. A closer examination of iPLA imaging in
non-activated pDCs revealed a weak but nevertheless pre-
existing interaction of TLR9 with MYD88 (Fig. 3e), that is
difﬁcult to visualise by conventional confocal microscopy, given
the relatively broad and overlapping intracellular distribution of
these molecules. A small fraction of processed endosomal TLR9 is
therefore readily available to detect DNA, explaining how the
response to CpG ODN and a wave UNC93B1-dependent TLR9
recruitment could be initiated16, 35.
TLR9 is targeted to an inducible VAMP3+LAMP2+ compart-
ment. We demonstrated that in the ﬁrst hour of pDCs activation,
BAD-LAMP loses its vicinity with UNC93B1 and associates or
Fig. 2 Graphical abstract of TLR9 trafﬁcking and signalling in human pDCs. a Graphical abstract summarizing the results shown in Fig. 1 on the
spatiotemporal organisation of endosomal TLR9 signalling in human pDCs. The bimodal regulation of TLR9 signalling as well as endosomal maturation is
represented using rectangles in shading red for IRF7-dependent phase and early endosome and in shading blue for NF-κB-dependent phase and late
endosomes
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remains associated with TLR9 in endosomes. We further
dissected BAD-LAMP and TLR9 intracellular transport by
following several markers of known endosome subsets. VAMP-3
is generally associated with recycling and sorting endosomes,
since it facilitates the transit of recycling receptors (e.g., Trans-
ferrin receptor)36. VAMP3 distribution was compared to LAMP1
one that mostly marks late endosomes and lysosomes, no
signiﬁcant overlap between the two molecules was observed at
any time during pDC activation (Fig. 4a and Supplementary
Fig. 3A). Unexpectedly, LAMP2, which is normally found tightly
associated in late endosomes with LAMP1, was found to segregate
from LAMP1-positive compartments after 1 h of CpG activation
and to acquire a common localisation with VAMP3 (Fig. 4a white
arrows, Pearson’s coefﬁcient right and voxel gating in
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Supplementary Fig. 3B). This dynamic process peaked at 3 h of
CpG activation, before returning to a steady-state distribution
with LAMP2 again mostly overlapping with LAMP1, away from
VAMP3 (Fig. 3a). CpG ODN stimulation induces therefore a
rapid reorganisation of endosomes in pDC, during which VAMP-
3 and LAMP2 are co-distributed in a hybrid compartment dis-
tinct from classical late LAMP1+ compartments. 3D reconstruc-
tion of several sets of images (Supplementary Fig. 3A), further
indicated that LAMP1 and LAMP2 are separated in distinct
domains of the same late endosomes segregated from VAMP3+
organelles. Upon the ﬁrst hours of pDC activation, partitioning of
LAMP1 and LAMP2 was increased, while LAMP2 and VAMP3
initiated to merge in one or several continuous compartments,
independently of LAMP1 distribution (Supplementary Fig. 3A
and Fig. 5a). Finally, the endosomal system returned to equili-
brium after 6 h of CpG ODN stimulation with the restoration
of LAMP1/LAMP2 co-distribution and disappearance of the
mixed compartment containing both VAMP3 and LAMP2
(Supplementary Fig. 3A).
Upon activation, TLR9 was found to access immediately
VAMP3+ compartments prior exiting from these endosomes
and entering in late LAMP1+ compartments 3 to 6 h after CpG
exposure (Fig. 4b white arrows, and Supplementary Fig. 4A).
Interestingly MYD88 distribution followed closely TLR9 trafﬁck-
ing, co-localising with VAMP3 and LAMP2 in the early phase of
activation (Fig. 4c) and augmenting its distribution within classical
LAMP1/LAMP2 double-positive late endosomes later on (Fig. 4c).
IRF7 recruitment in the hybrid compartment was conﬁrmed by
voxel gating imaging showing that TLR9, IRF7 co-localise with
VAMP-3+ and LAMP2+ upon 1-3 h of CpG stimulation,
suggesting that CpG activation primarily drives TLR9/MYD88
association in VAMP-3+/LAMP2+ organelles, from which IRF7
activation is initiated (Supplementary Fig. 3B). After 6 h of
activation, concomitantly with LAMP2 redistribution, TLR9 and
MYD88 were found in late LAMP1+ endosomes from which they
likely trigger NF-κB activation (Fig. 4c and Supplementary
Fig. 3B). During this process, BAD-LAMP, together with TLR9
and MYD88, reached VAMP3+ endosomes at early time points
(Fig. 4d and Supplementary Fig. 4A), prior disappearing gradually
during time (Fig. 4d). Given the dynamic nature of VAMP3+
endosomes, we further deﬁned their molecular identity by using
Syntaxin 6 (STX6), which is a SNARE associated with post-TGN
endosomes. VAMP3 sub-distributed in two types of organelles, in
a pericentriolar compartment positive for STX6, and alternatively
in a population of peripheral endosomes negative for STX6
(Supplementary Fig. 4A). Upon CpG activation, BAD-LAMP and
TLR9 were found to accumulate exclusively in VAMP3+
peripheral endosomes, while pericentriolar STX6+/VAMP3+
organelles remained devoid of staining (Supplementary Fig. 4A),
in accordance with their presumed recycling endosomes
identity37.
Since CpG-A ODN trafﬁc through different signalling
compartments sets the pace for pDCs activation, we imaged
soluble ﬂuorescent CpG-A distribution after uptake by primary
pDCs and CAL-1 over time (Supplementary Fig. 4C, D). CpG-A
followed the same intracellular path previously observed for TLR9
and MYD88, being ﬁrst in direct vicinity of TLR9 and BAD-
LAMP in VAMP3+/LAMP2+ compartment, and then accessing at
later time the LAMP1+ late endosomes (Supplementary Fig. 4C,
D white arrows). Thus, in human pDCs, TLR9 activation by CpG-
A is spatiotemporally organised by ﬁrst triggering type-I IFN
expression in an inducible VAMP3+/LAMP2+ chimeric endoso-
mal compartment, prior initiating pro-inﬂammatory cytokines
production from conventional LAMP1+ late endocytic compart-
ments (Fig. 5a). This situation is strikingly converse to what has
been previously observed in mouse macrophages21, 38, but in line
with results dissecting CpG-A activity on mouse DC39.
BAD-LAMP inhibits type I IFN induction by CpG ODN. We
next silenced BAD-LAMP expression in CAL-1 cells to address its
possible role on TLR9 trafﬁcking and signalling. RNA inter-
ference was performed using as positive control, UNC93B1
siRNA, which should abolish the pDC response to CpG ODN.
Upon siRNA introduction, BAD-LAMP expression was efﬁciently
downregulated both at the mRNA and protein level (Supple-
mentary Fig. 5A), while scramble siRNA did not interfere with
BAD-LAMP expression at steady state, nor with its down-
modulation upon stimulation. Conversely, UNC93B1 silencing by
blocking TLR9 recruitment to endosomes (Fig. 6a) prevented
pDC activation and associated BAD-LAMP decay (Supplemen-
tary Fig. 5A). Importantly, BAD-LAMP silencing strongly affec-
ted TLR9 trafﬁcking and promoted its accumulation in VAMP3+
compartments, while sorting to LAMP1+ late endosomes was
inhibited over time (Fig. 6a). This was particularly obvious in
non-stimulated cells in which BAD-LAMP silencing induced a
strong co-localisation of TLR9 with VAMP3, equivalent to what
is observed after 3 h of CpG activation (Fig. 6a) and completely
absent from cells treated with scramble siRNA. Mirroring its
accumulation in VAMP3 + compartments, TLR9 co-localisation
with LAMP1 was considerably decreased upon BAD-LAMP
extinction (Fig. 6a). All these observations were conﬁrmed by
performing iPLA on RNAi-treated cells (Supplementary Fig. 5B)
in which BAD-LAMP silencing induced a strong and persistent
accumulation of TLR9 in close vicinity of VAMP3 and promoted
IRF7 recruitment to this compartment (Supplementary Fig. 5C).
We investigated how enhanced accumulation of TLR9 and
IRF7 in VAMP3+ peripheral endosomes impacted signalling in
Fig. 3 BAD-LAMP is co-localised with TLR9 and MYD88 upon activation by CpG. a (left) Immunoﬂuorescence confocal microscopy (ICM) of CAL-1 and
freshly isolated pDCs stimulated or not (NS) with CpG-A for indicated times was performed to visualise BAD-LAMP (green), MYD88 (red) and TLR9
(cyan). Arrowheads point at co-localisation area. (right) Co-localisation quantiﬁcations using Pearson’s coefﬁcient measurement (ImageJ) are shown for
TLR9 and BAD-LAMP (red line), MYD88 and TLR9 (black line), MYD88 and BAD-LAMP (dashed line) during time. Graphics represent Pearson’s coefﬁcient
means of 50 different cells± s.d. for each time point from at least three independent experiments. b Voxel gating analysis of immunoﬂuorescence confocal
images of CAL-1 cells presented in a. Voxel gating was performed on TLR9 (cyan) and MYD88 (red) channels to generate a ‘coloc channel’ picture only
showing co-localisation areas between the two proteins. This ‘coloc channel’ was then merged with single BAD-LAMP staining to obtain simpliﬁed tri-
localisation images, revealing strong BAD-LAMP co-localisation with TLR9/MYD88 after 1 h of CpG-A exposure. Scale bars= 5 μM.
c–e Immunoﬂuorescence proximity ligation assay (iPLA) on CAL-1 or freshly isolated pDCs stimulated with CpG-A for indicated times performed for
BAD-LAMP and UNC93B1 (c), BAD-LAMP and TLR9 (d), and TLR9 and MYD88 (e). (left) Confocal images are representative of at least three
independent experiments in which the nucleus is stained by DAPI (blue) and proximity between the two proteins of interest is revealed by incorporation of
labelled nucleotide (red) during the ligation reaction. Scale bars= 10 μM. (right) Quantiﬁcation of iPLA for pDCs (black line) and CAL-1 (dashed line) by
counting the number of red dots normalised to nucleus numbers using imageJ. Graphics are representing means of dots/cell for 150 different cells± s.d.
from at least three independent experiments. The bimodal regulation of TLR9 signalling is represented with a shading red rectangle for its IRF7-dependent
phase and blue for its NF-κB-dependent phase
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silenced cells by monitoring INF-α2 and TNFαmRNA expression
after CpG stimulation (Fig. 6b). As expected, UNC93B1 silencing
prevented the induction of both cytokines, while the scramble
control had little effect on the bimodal induction of INFα2 and
TNFα by CpG (Fig. 6b). Importantly, BAD-LAMP silencing
induced INFα2 mRNA expression in absence of any CpG
stimulation (8 folds over control) (Fig. 6b), correlating with the
strong accumulation of TLR9 in VAMP3+ endosomes at steady
state (Fig. 6a). This enhancement was conﬁrmed after CpG
treatment, since a 10-fold increase over control in INFα2 mRNA
levels was observed in BAD-LAMP-silenced cells after only 1 h
of stimulation, while type-I IFN secretion was augmented
threefold after 6 h (Fig. 6c). Increased IFN levels were inversely
correlated with TNF expression (Figs. 4c and 6b), which was
inhibited by BAD-LAMP silencing, both at the transcriptional
and protein secretion levels. Importantly BAD-LAMP disappear-
ance did not impair CpG internalisation (Supplementary Fig. 5D),
nor LAMP2 redistribution with VAMP3 (Supplementary Fig. 5E),
suggesting that BAD-LAMP regulates the temporal organisation
of different signals transduced upon CpG ODN detection mostly
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by interfering with TLR9 sorting and residency in VAMP3+
endosomes (Fig. 5b). The phosphorylation/activation kinetics of
TBK1, IRF7, AKT and NF-κB (p65) in silenced CAL-1 cells
conﬁrmed this hypothesis (Fig. 6d and Supplementary Fig. 5E),
since in absence of BAD-LAMP, TBK1 (MFI) and IRF7
phosphorylation was already increased prior by CpG stimulation
and maintained for at least 6 h, while P-p65 levels were never
increased compared to scramble control. Interestingly, AKT
activation was also reinforced in BAD-LAMP-silenced cells,
suggesting that AKT activation by TLR9 is also triggered from
a
b c
d
Fig. 5 Graphical abstracts of TLR9 trafﬁcking and signalling in human pDCs upon activation or BAD-LAMP manipulation. a Graphical abstract summarizing
the results shown in Fig. 4 on the spatiotemporal organisation of endosomes and TLR9 signalling in CpG-activated human pDCs. b Graphical abstract
summarizing the results shown in Fig. 6 on the spatiotemporal organisation of endosomes and TLR9 signalling upon BAD-LAMP silencing. c Graphical
abstract summarising the results shown in Fig. 7 on the spatiotemporal organisation of endosomes and TLR9 signalling upon overexpression of BAD-
LAMP. d Graphical abstract summarising the results shown in Fig. 9 on the spatiotemporal organisation of endosomes and TLR9 signalling,
upon overexpression of BAD-LAMP bearing a mutation in its YxxΦ addressing signal. The bimodal regulation of TLR9 signalling as well as endosomal
maturation is represented using rectangles in shading red for IRF7-dependent phase and early endosome and in shading blue for NF-κB-dependent phase and
late endosomes
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VAMP3-positive endosomes, in agreement with previous
observations demonstrating that AKT activation occurs within
20 min of pDC stimulation by CpG or Flu40.
Given the tight control on BAD-LAMP expression exerted by
TLR9 activation, we evaluated the consequences of increasing
BAD-LAMP levels in CAL-1 cells. After electroporation of
BAD-LAMP mRNA, protein levels were maintained for at least
6 h after CpG treatment (Supplementary Fig. 6A). Overexpression
strongly increased BAD-LAMP subcellular co-localisation with
LAMP1 both at steady state and upon activation (Fig. 7a),
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reminiscent of its distribution in Baﬁlomycin A1-treated cells
(Supplementary Fig. 2D). TLR9 transport to VAMP3+ compart-
ment was not affected by BAD-LAMP expression; however, its
accumulation in LAMP1+ endosome was strongly increased upon
stimulation (Fig. 7b). Enhanced TLR9 targeting to late endosome
was accompanied by a reduction in both INF-α2 mRNA
expression and secretion (Figs 6d and 7c), while TNF production
augmented (Figs 6d and 7c). Although, TLR9 could still be
detected in VAMP3+ endosome, its ability to signal was impaired
by BAD-LAMP overexpression, which prevented IRF7 recruit-
ment to these TLR9-containing compartments (Fig. 7e, voxel
gating). Inhibition of IRF7 recruitment by TLR9 on VAMP3+
endosomes was even more obvious when iPLA was performed on
BAD-LAMP-overexpressing cells (Supplementary Fig. 6B, C). In
line with TLR9 and IRF7 subcellular localisation, phosphorylation
of IRF7, AKT (Fig. 7f) and TBK1 (MFI) (Supplementary Fig. 6E)
in response to CpG-A was impaired by BAD-LAMP expression.
Conversely, NF-κB (p65) phosphorylation was enhanced, until
6 h of stimulation, a time at which it disappeared. Thus, although
BAD-LAMP prevents IRF7 recruitment and accelerates TLR9
access to late endosomes (Fig. 5c), the resulting increase in NF-κB
signalling is nevertheless negatively controlled with time,
explaining the transcription plateau observed for TNF mRNA
levels in Fig. 6c.
Again, these differences in TLR9 transport and associated
signalling triggered by BAD-LAMP ectopic expression, could not
be attributed to an indirect effect on membrane dynamic or
reorganisation, since organelles distribution was normal and
CpG-dependent induction of VAMP-3+/LAMP2+ compartments
remained unaffected by these treatments (Supplementary Fig. 6D).
Taken together both RNA silencing and overexpression experi-
ments, suggest a role for BAD-LAMP in regulating TLR9 signalling
by preventing IRF7 recruitment and facilitating sorting from
VAMP3+ endosomes to LAMP1 lysosomes (Fig. 5b, c).
AP-3 and BAD-LAMP YxxΦ motif control TLR9 transport.
Earlier work, monitoring TLR9-GFP ectopic expression in
adaptor protein 3 (AP-3) −/− mouse macrophages, has pointed
towards a bifurcation of TLR9 transport, which, when targeted by
AP-3 to LAMP2+ lysosome-related organelles (LRO), recruits
IRF7 and induces type-I IFN21. Whether AP-3 is also required
for TNF production remains controversial24, since later work
proposed that the carboxyl-terminal tyrosine-based sorting
motif (YxxΦ) embedded in the TLR9 cytoplasmic tail allows
phosphorylation and TLR9 targeting to late endosomes from
which TNF expression is triggered in response to CpG ODN41, 42.
We therefore took advantage of our capacity to perform RNA
interference in CAL-1 cells and revisited these ﬁnding by inves-
tigating the impact of AP-3 silencing on human pDCs activation
and BAD-LAMP transport, since it bears a ‘YKHM’ motif at the
extremity (aa 276-280) of its cytoplasmic tail26.
AP-3 was imaged together with TLR9 and BAD-LAMP in
CpG-stimulated CAL-1 cells (Fig. 8a). TLR9 co-distribution with
AP-3 was increased during the ﬁrst hour of activation and
remained nearly unchanged afterwards (Fig. 8a). BAD-LAMP
distribution with the adaptor followed the same trend until its
disappearance at 6 h (Fig. 8a). Efﬁcient AP-3β (Supplementary
Fig. 7A, B) silencing increased considerably BAD-LAMP (Fig. 8b)
and TLR9 (Fig. 8c) co-distribution in VAMP3+ compartments,
while TLR9 access to LAMP1-positive compartment, observed in
control cells, was prevented (Fig. 8c). AP-3β silencing also largely
impacted the formation of VAMP3+/LAMP2+ endo-lysosomes,
compromising the induction and the clear segregation of this
hybrid compartment, as judged by the overlapping distribution of
all three endosomal markers used in the study (Supplementary
Fig. 7C). AP-3β silencing also increased considerably TLR9 and
BAD-LAMP co-localisation in both resting and CpG-stimulated
cells suggesting that BAD-LAMP sorting is also affected by AP-3
deﬁciency (Supplementary Fig. 7D). As anticipated from TLR9
accumulation in VAMP3+ endosomes, CpG activation strongly
augmented IFNα2 transcription in silenced cells (Fig. 8d), while
TNF-α mRNA expression was reduced (Fig. 8d).
Given that BAD-LAMP bears a carboxyl-terminal YxxΦ motif,
we also evaluated the importance of this AP-2/3 dependent
sorting signal for TLR9 transport and signalling, by introducing a
mutational change from tyrosine to alanine at position 276 in the
cytoplasmic tail of BAD-LAMP (BAD-LAMP Y276A). We then
compared the effect of ectopic expression of Flag-BAD-LAMP
WT to Flag-BAD-LAMP Y276A on TLR9 localisation and
signalling in CAL-1 cells. After electroporation of mRNAs coding
for WT or mutant BAD-LAMP, protein levels (Flag staining)
were maintained for at least 6 h after CpG treatment (Fig. 9a).
BAD-LAMP Y276A accumulation in VAMP3 endosome was
strongly enhanced compare to the WT molecule and its transport
to LAMP1 endosomes was completely prevented (Fig. 9b). In
agreement with this result, BAD-LAMP Y276A expression had no
consequences on both TLR9 localisation (Fig. 9c) and cytokines
expression (Fig. 9d), thus acting as a dead mutant.
Taken together, those results strongly indicate that the ‘YKHM’
motif of BAD-LAMP is necessary for its transport from VAMP3+
endosomes to late endosomes and the inhibition of IRF7
recruitment by TLR9 (Fig. 5d). Moreover, in human pDCs,
AP-3 is necessary to maintain a normal endosome dynamic and
compartmentalisation that is required by TLR9 and probably
BAD-LAMP to reach LAMP1+ endosomes. Notably, increased
Fig. 7 BAD-LAMP expression promotes TLR9-dependent TNF expression. CAL-1 cells were electroporated with BAD-LAMP mRNA (overexpressed
BAD-LAMP) or control non-relevant mRNA (NT) during 6 h before stimulation during indicated times with CpG. a, b (left) Immunoﬂuorescence confocal
microscopy (ICM) on CAL-1 electroporated with BAD-LAMP mRNA or not and stimulated with CpG-A for indicated times. Staining for LAMP1, VAMP3
and BAD-LAMP (a) or TLR9 (b) is shown. Pictures are representative of at least three independent experiments. White arrowheads identify co-localisation
area. Scale bars= 5 µm. (right) Quantiﬁcation of the co-localisation between BAD-LAMP (a) or TLR9 (b) and VAMP3 (red lines) or LAMP1 (blue lines)
between control (full lines) and transfected cells (dashed lines) upon CpG-A stimulation was performed by Pearson’s coefﬁcient measurement using ImageJ.
Graphics represents mean of Pearson’s coefﬁcient of at least 25 cells± s.d. for any time point. c, d IFNα2 (left) and TNF (right) mRNA (c) or protein (d)
level were monitored by RT-QPCR or ELISA respectively. e (top) Voxel gating analysis after ICM on control (NT) or transfected cells with BAD-LAMP
mRNA and treated during 3 h with CpG-A. Voxel gating was performed on TLR9 (green) and VAMP3 (red) channels to generate a ‘Coloc channel’
picture only showing VAMP3+ TLR9-containing endosomes. This new ‘Coloc channel’ was then merged with single IRF7 staining. Arrowhead indicates
co-localisation area. Scale bars= 5 µm. (bottom) Quantiﬁcation was performed by Pearson’s coefﬁcient measurement using ImageJ. Graphics represent
Pearson’s coefﬁcient means of 25 different cells± s.d. from two independent experiments. f (left) control CAL-1 cells or expressing FLAG-BAD-LAMP
mRNA were treated with CpG-A for indicated times prior lysis and sodium dodecyl sulphate–polyacrylamide gel electrophoresis treatment. Expression of
FLAG, AKT, IRF7, p65 NF-κB subunit and their phosphorylated forms were detected by immunoblot. β-actin is shown as loading control. (right)
Quantiﬁcation of IRF7 (top) and p65 (bottom) phosphorylation levels normalised to their total form by ImageJ quantiﬁcation. *P< 0.05 by unpaired
student’s t-test
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distribution of TLR9 in VAMP3+ endosomes always correlates
with stronger early type-I IFN expression and reduced TNF-α
mRNA levels. A role for LAMP1+ late endosomes or lysosomes
as signalling hubs capable of promoting IFN expression in human
pDCs in response to CpG seems however excluded by our results
(Fig. 5).
BAD-LAMP prevents type I IFN production in tumour pDCs.
Given the role of BAD-LAMP in controlling TLR9 signalling
through endosomes sorting, we wondered whether immunomo-
dulatory conditions known to inﬂuence pDCs function could
interfere with BAD-LAMP expression or activity. Human pDCs
inﬁltrating tumours can be functionally impaired and contribute
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to the abnormal regulatory T cells ampliﬁcation associated
with poor prognosis29, 43. This negative impact of breast tumour-
associated pDCs (TA-pDCs) on clinical outcomes has been
linked to an IFN-α production defect driven by tumour-derived
soluble factors, like transforming growth factor-β (TGF-β)44.
Using BDCA2 and CD123 as selective markers, we quantiﬁed
comparatively BAD-LAMP levels in pDCs isolated from the
tumour and from the peripheral blood of the same patients
(Fig. 10a). By ﬂow cytometry analysis, BAD-LAMP levels wer-
e found strongly up-regulated in breast TA-pDCs compared to
their blood counterparts. As BAD-LAMP levels correlated with the
dysfunctional status of TA-pDCs, we examined the consequences
of treating pDCs in vitro with tumours supernatants (snTUM)
known to have or not immunosuppressive activity (Fig. 10b).
Short-term treatment of blood pDCs with immunosuppressive
supernatants containing TNF-α and high levels of TGF-β
(snTUM+)44, prevented BAD-LAMP downregulation in response
to CpG activation, unlike treatment with non-immunosuppressive
supernatants (snTUM-). When tumour supernatants were sub-
stituted by a combination of puriﬁed TGF-β and TNF-α, similar
results were obtained with CpG-activated CAL-1 cells. Next, a
combination of puriﬁed TGF-β and TNF-α was used to replace
immunosupressive tumour supernatants with similar con-
sequences on CAL-1 cells activation by CpG, thus conﬁrming that
TGF-β prevents the down-modulation of BAD-LAMP in activated
pDCs (Supplementary Fig. 8A, B). Not surprisingly, type-I IFN
mRNA expression was strongly inhibited in these cells (Figs 10c, d,
Supplementary Fig. 8C), while TNF production remained howe-
ver unaffected in the ﬁrst hours of activation (Figs 10c, d and
Supplementary Fig. 8C). TLR9 triggering by CpG was therefore
not completely impaired by TGF-β or snTUM+ exposure, which
impacted mostly type-I IFN expression. Given that BAD-LAMP
reduces the capacity of TLR9 to trigger type-I IFN transcription,
we hypothesised that a negative ampliﬁcation loop initiated by
TGF-β exposure and by reinforced BAD-LAMP expression could
explain partly the dysfunctional status of tumour-associated pDCs.
We therefore silenced BAD-LAMP in CAL-1 cells exposed to the
immunosuppressive cytokines cocktail, and monitored their
capacity to respond to CpG (Fig. 10e). BAD-LAMP silencing
prevented the complete extinction of type-I IFN expression in
response to CpG normally caused by TGF-β, and allowed TGF-β-
treated cells to maintain IFN-α2 transcription levels equivalent to
scramble control, while TNF expression remained unaffected
(Fig. 10e). Taken together, these results again underline the
importance of BAD-LAMP expression in controlling
TLR9 signalling and suggest that its reinforced expression in
tumour-associated pDCs contributes to their immunomodulatory
phenotypes by decreasing the type-I IFN production capacity.
Discussion
Plasmacytoid dendritic cells are important actors of antiviral
immunity that produce large amounts of type-I IFN in response
to nucleic acid detection by TLR7 and TLR9. Another fascinating
aspect of pDCs biology is their ability to develop into tolerogenic
DCs, driven by endogenous factors including cytokines and T-cell
derived signals that may constitute an important self-tolerance
mechanism during tumour development. The nature and the
dynamic of the endosomes serving as assembly hubs for different
TLRs signalling complexes is the driving force behind pDC’s
response to nucleic acids. Human pDCs have adopted a dynamic
endosomes organisation, which favours intense type-I IFN
production by allowing rapid signalling from early endosomal
compartments. The inducible and transient existence of these
chimeric organelles suggests that they could be considered as
functional intermediates between sorting endosomes and LRO45.
Such compartments present a mixed identity failing to completely
segregate in speciﬁc endosomal subsets and are the results of
active endosome reorganisation, as previously reported for MHC
II-containing organelles in activated conventional DC46 or in
HeLa cell47. Hybrid compartments seem therefore to be a feature
of cells controlling tightly their endosomes dynamic in response
to immune-regulatory cues and could be key to modulate the
balance and the strength of the signalling required to optimise
cytokine production.
Our data suggest that AP-3 participates in this endosomal
reorganisation and allows TLR9 and BAD-LAMP to access late
endosomes from which TNF expression can be induced. Given
the massive disturbance in endosome dynamics caused by AP-3
silencing, it would be extremely speculative to further assign a
speciﬁc role for this adaptor in TLR9 sorting. However, we
could not observe any early type-I IFN production impairment in
AP-3-silenced CAL-1 cells, conﬁrming that TLR9 signalling from
VAMP3+ organelles is sufﬁcient to drive early IFN-α expression
in pDC. These observations are in agreement with the fact that
not all CpG ODN types can trigger type-I IFN production, a
capacity mostly reserved to multimeric CpG ODNs accumulating
in early endosomes, such as CPG-A39. The bimodal mode of
TLR9 triggering that allows NF-κB activation to be initiated from
LAMP1+ late endosomes several hours post CpG-A exposure,
suggests that these signalling cascades have evolved to present
different thresholds of activation in various cell types and perhaps
species. The equilibrium and the signalling strength emanating
from these pathways is also strongly inﬂuenced by the immu-
nological environment, such as pre-exposure to type-I IFN, TNF
or TGF-β, which we have shown here all impact BAD-LAMP
expression and consequently the polarity of TLR9 signalling.
The mutually exclusive co-localisation of UNC93B1 and TLR9
with BAD-LAMP in endosomes suggests a sequential mode of
interaction during which, association with UNC93B1 allows
TLR9 addressing to VAMP3+ endosomes, before BAD-LAMP-
dependent sorting. In turn BAD-LAMP facilitates TLR9 transport
to late endosomes and potentially increases its degradation,
while inhibiting the signalling cascades leading to type-I IFN
production. We have shown that BAD-LAMP and UNC93B1 are
capable of co-localising together upon overexpression28, whether
Fig. 8 AP-3 is necessary for TLR9 sorting to LAMP1 lysosomes and TNF induction. a (left) Immunoﬂuorescence confocal microscopy (ICM) on CAL-1
stimulated with CpG-A for indicated times. Staining for BAD-LAMP, TLR9, and AP-3 is shown. Pictures are representative of at least three independent
experiments. Arrowheads indicate co-localisation area. Scale bars= 5 μM. (right) Quantiﬁcation of the co-localisation between TLR9 and BAD-LAMP
(black line as reference), AP-3 and BAD-LAMP (top graph red line), and AP-3 and TLR9 (bottom graph red line) at different time was performed by Pearson’s
coefﬁcient measurement using ImageJ. b, c (left) Immunoﬂuorescence confocal microscopy on CAL-1 electroporated with AP-3 siRNA or scramble siRNA
and stimulated with CpG-A for indicated times. Stainings for LAMP1, VAMP3 and BAD-LAMP (b) or TLR9 (c) are shown. These pictures are representative
of at least three independent experiments. White arrows identiﬁed co-localisation area. Scale bars= 5Mm. right Quantiﬁcation of the co-localisation between
BAD-LAMP (b) or TLR9 (c) with VAMP3 (top) or LAMP1 (bottom) at steady state (NS) or 3 h upon CpG-A stimulation was performed by Pearson’s
coefﬁcient using ImageJ. Graphics represent Pearson’s coefﬁcient means of 50 different cells± s.d. from at least three independent experiments. d IFNα2
(left) and TNF (right) mRNA level were monitored by RT-QPCR. Raw data have been normalised to housekeeping gene (GAPDH) and graphics represent fold
change± s.d. compare to non-stimulated cells from three independent experiments minimum. *P< 0.05 by unpaired student’s t-test
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WT or FLAG BAD-LAMP Y276A mRNAs for 6 h prior stimulation for indicated times with CpG-A. Mock electroporated cells (NT) are used as control.
a BAD-LAMP ectopic protein expression were monitored by intracellular ﬂow cytometry with FLAG tag antibody. Graphic represents means of MFI± s.d.
from at least two independent experiments. b, c (left) Immunoﬂuorescence confocal microscopy on CAL-1 cells. Staining for LAMP1, VAMP3, FLAG (b) or
TLR9 (c) are shown. Pictures are representative of at least two independent experiments.White arrows identify co-localisation area. Scale bars= 5 μM. (right)
Quantiﬁcation of the co-localisation between FLAG (b) or TLR9 (c) with VAMP3 (top) or LAMP1 (bottom) at steady state (NS) and 3 h after CpG-A
stimulation was performed by Pearson’s coefﬁcient measurement using ImageJ. Graphics represents mean of Pearson’s coefﬁcient of at least 25 cells± s.d.
for all time points. d IFNα2 (left) and TNF (right) mRNA level were monitored by RT-QPCR. Raw data have been normalised to housekeeping gene (GAPDH)
and graphics represent fold change± s.d. compare to non-stimulated cells from two independent experiments. *P< 0.05 by unpaired student’s t-test
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00695-1
14 NATURE COMMUNICATIONS | 8:  913 |DOI: 10.1038/s41467-017-00695-1 |www.nature.com/naturecommunications
this co-localisation is exclusive and interferes with binding to
endocytic TLRs remains to be clariﬁed. Until now, most of the
biochemistry and cell biology performed on TLR9 and its inter-
actors have been carried-out using overexpressed tagged-proteins
(in particular TLR9-GFP) in non-relevant cell lines. Given that
quality antibodies allowing a good human TLR9 biochemical
analysis are not available, we had to turn to advanced microscopy
techniques to evaluate the interactions of BAD-LAMP, UNC93B1
and TLR9 in primary human pDCs. iPLA was of great efﬁcacy to
demonstrate the close vicinity and likely interactions of these
different endogenous molecules during time, however until now
our attempts to demonstrate unequivocally a physical binding
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using traditional co-immunoprecipitation methods remained
unsuccessful.
Using UNC93B1 silencing, we however showed that
BAD-LAMP depends on this chaperone and/or pDC activation
to reach massively VAMP3+ endosomes with TLR9 (Fig. 6a),
suggesting that UNC93B1 and BAD-LAMP interaction in the ER
or ERGIC could be part of the regulatory process controlling
TLR9 transport in pDC. Interestingly, TLR9 accumulation at
steady state in VAMP3+ compartments upon BAD-LAMP-
silencing, further suggests that a constant but limited ﬂow of
BAD-LAMP and TLR9 molecules can reach endosomes inde-
pendently of pDC activation. Upon DNA detection, this TLR9
pool could be responsible for the ﬁrst signalling events initiating
the massive UNC93B1-dependent endosome recruitment of
ER-resident TLR9 required for potent type-I IFN production.
BAD-LAMP expression seems however to limit the activation of
this pool, presumably by promoting TLR9 transport to late
endosomes, whose degradative environment could increase the
threshold of TLR9 activation by endogenous ligands, compared to
the situation in VAMP3+ compartments.
To preserve the organism from the inherent toxicity of
recurrent and excessive release of type I IFN, it is crucial that
pDCs avoid inappropriate activation by circulating self-DNA, but
still respond to microbial cues48. This issue is particularly relevant
to human pDCs, since their extreme specialisation as professional
IFN-producers is dwarﬁng their mouse counterparts. It has
been proposed that responses to self-DNA are limited by
the requirement for endocytosis and residency time with
TLR9/MYD88 complexes in early endosomes19, 49. The capacity
of BAD-LAMP to decrease TLR9 capacity to drive IFN responses
suggests that human pDCs require additional safeguards
mechanisms to limit abnormal type-I IFN production and
regulate their capacity to produce pro-inﬂammatory cytokines.
BAD-LAMP expression seems to maintain a molecular safety
lock on TLR9 signalling by reducing its capacity to produce
spontaneously type-I IFN. During the early phase of activation,
BAD-LAMP allows TLR9 to reach late endosomes from which
NF-κB activation can occur, if appropriate quantities of nucleic
acid ligands are present in these compartments. If pDC exposure
to type-I IFN prevails, BAD-LAMP down-regulation facilitates
TLR9 retention and signalling from VAMP3+/LAMP2+
compartments allowing a positive-ampliﬁcation loop increasing
IFN production. BAD-LAMP expression levels are therefore
correlated with the reduced capacity of pDCs to produce type-I
IFN and increased potential to develop into tolerogenic DCs. This
particular feature of BAD-LAMP seems to be exploited in tumour
inﬁltrating pDCs, since higher expression of BAD-LAMP in
pDCs exposed to tumour microenvironments contribute to their
functional impairment and incapacity to produce type-I IFN,
both associated with poor prognosis. BAD-LAMP therapeutic
modulation could therefore represent a novel strategy for
harnessing pDCs responses in different clinically relevant
contexts such as autoimmunity or tumour development.
Methods
Patients, human tissue samples and blood. Fresh tumours from patients
diagnosed with primary breast carcinoma were obtained prior any treatment from
the Centre Léon Bérard (CLB) tissue bank after patient informed consent. The
study was reviewed and approved by the Institutional Review Board of CLB, Lyon.
Discarded human tonsil material was obtained anonymously according to the
institutional regulations in compliance with French law. Written informed consent
was obtained from all study participants in accordance with the Declaration of
Helsinki. Healthy human blood and Buffy coats were obtained by leukapheresis
(Etablissement Français du Sang (EFS) Marseille, France). The CAL-1 cells were
the kind gift of Dr. Takahiro Maeda from Nagasaki University Graduate school of
Biomedical Science, Japan.
Isolation and stimulation of pDCs. Mononuclear cell enriched from blood of
healthy donors was submitted to Ficoll-paque plus and percoll gradient (all from
PBL Biomedical Laboratories). The pDCs were MACS sorted using a negative
selection kit as per manufacturer’s instructions (plasmacytoïd dendritic cells II
Miltenyi biotec). The pDCs isolated by this procedure were 93–98% pure and their
viability was > 95%. Healthy pDCs were cultured in the presence of IL-3 (1ng/ml)
and stimulated with CpG-A ODN 2216 (Tebu bio) for indicated time. Cell
culture with breast tumour supernatant (TumSN) was performed as described in
supplementary methods44. Cal-1 cells (the kind gift of Dr. T. Maeda Nagasaki
University, Japan) were grown in RPMI (GIBCO), 10% FCS (Sigma Aldrich), 2mM
L-glutamine, 1x non-essential amino acids, 10 mM HEPES, 1 mM sodium pyruvate
(all the previous from GIBCO). For performing experiments, cells were plated 16 h
before in a 12 wells plate at 1 × 106 cells/ml, 1 ml × well, in a complete medium
with 1% FCS. All cell lines were mycoplasma free and kept at 37°C and 5% CO2.
Detection of cytokines. ELISA kit for human type I IFN dosage in CAL-1
supernatants was from PBL Biomedical Laboratories. ELISA kit for human IFNα1
dosage in freshly isolated pDCs supernatants and for human TNF were from
eBiosciences. All were used according to manufacturer’s instructions and described
in Supplementary Table 2.
Proximity ligation assays. CAL-1 and freshly isolated pDCs were activated for the
indicated time and treated as for conventional immunoﬂuorescence microscopy.
Secondary PLA probes were from Sigma and ligation and Red Ampliﬁcation
solutions were used according to manufacturer’s instructions. Washed cells were
mounted on microscopy slide using Duolink II Mounting Medium with DAPI.
Image stacks were captured with an inverted confocal microscope Zeiss LSM580 or
a Leica TCS SPX5, using 63× objective and accompanying imaging softwares
described in Supplementary Table 2. The images were quantiﬁed using the analyse
particles plugin of ImageJ.
Antibodies and immunodetection. 25–50 µg of NP-40 soluble material was
separated by 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis
prior immunoblotting and chemiluminescence detection (Pierce), original
uncropped immunoblots are shown in Supplementary Figs 9–13. Antibodies used
in this study were: Rat mAb 34.2 anti-BAD-LAMP (LAMP5)26, rabbit polyclonal
Fig. 10 BAD-LAMP expression in tumour-associated pDCs correlates with low IFN-α production. a (left) Flow cytometry pDC gating strategy on both
PBMC (top) and tumour (bottom) is shown. pDCs (BDCA2+; CD123+) were segregated from conventional dendritic cells (Lin−, MHC II high) after
identiﬁcation of live hematopoietic cells (CD45+ Live Dead−). (right) CD123+/BDCA4+ pDCs from blood (black) or from primary breast tumours (red) were
further analysed for BAD-LAMP and MHC II expression. Data are representative of three patients. b Freshly isolated pDCs from healthy donors were
treated for 16 h with tumour supernatant either devoid of (snTUM−) or enriched in (snTUM+) TNF and TGF-β. (left) BAD-LAMP and MHC II histogram
plots from FACS staining at steady state (black line) or 24 h (dashed line) after CpG-A treatment. Full grey histogram represents isotype control. Data are
representative for ﬁve independent experiments performed with eight different tumour supernatants. (right) Levels of BAD-LAMP shown as MFI from
FACS intracellular staining in pDCs pre-treated with snTUM- (dashed line), snTUM+ (red line) or with medium (black lines). MFI± s.d. from ﬁve
independent experiments. c Freshly isolated pDCs from heathy donors were treated for 16 h with tumour supernatant either devoid of (snTUM-; black) or
enriched in (snTUM+ ; red) in TNF and TGF-β. 2D FACS analysis of intracellular staining for IFN-α and TNF cytokines at different times after CpG-A
stimulation. Data are representative for three independent experiments. d IFN-α (top) and TNF (bottom) production was monitored by ELISA at different
times of CpG-A stimulation. Graphics represent cytokines concentration± s.d. from ﬁve independent experiments minimum. Eight different sets of tumour
supernatants have been tested. e IFNα2 (left) and TNF (right) mRNA expression in CAL-1 electroporated with BAD-LAMP siRNA (dashed lines) or
scramble siRNA (full lines) and stimulated for indicated times with CpG-A. CAL-1 were treated either with TNF + TGF-β (coloured) or with medium (black).
Raw data have been normalised to housekeeping gene (GAPDH) and graphics represent fold± s.d. compared to non-stimulated cells from two experiment.
*P< 0.05 by unpaired student’s t-test
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anti-, phospho-p65, phospho-S6, S6, phospho-IRF7, phospho-TBK1 were from
Cell Signalling Technology, anti-IRF7 was from Santa Cruz, anti-p65, anti-TLR9
(H-100), anti-UNC93B1 (E-12) were all from Santa Cruz biotechnology.
Anti-VAMP3 was the kind gift from Thierry Galli (Institut J. Monod, Paris).
Anti-ﬂag was purchased from Sigma. Goat polyclonal anti-VAMP3 (N12) was
from Santa Cruz biotechnology and anti-MYD88 from R&D System. Anti-Mouse
monoclonal anti-actin (AC-15), anti-Syntaxin 6 and anti-AP-3 were all from BD
transduction laboratories. Brilliant violet 421 and anti-LAMP1 (H4A3) were from
Biolegend. Alexa ﬂuor 647 anti-LAMP2 (H4A3) were from Molecular probes.
Secondary antibodies were from Jackson Immunoresearch, Molecular Probes
and Cell Signalling Technology. For immunoﬂuorescence, cells seeded on alcian
blue-treated coverslips were ﬁxed with 3.5% PFA and permeabilized with 0.05%
saponin. Immunoﬂuorescence and confocal microscopy was performed with a
Zeiss LSM580 or a Leica TCS SPX5 using a 63 x objective and accompanying
imaging softwares described in Supplementary Table 2. Fluorochrome- or
biotin-coupled antibodies for FACS were CD123 (6H6), anti TNF-alpha (MAb11),
LAMP5 (34.2) were all from eBioscience. Anti-CD303 (201A), CD304 (12C2) were
from Biolegend and anti-IFNα (LT27:295) from miltenyi biotech. All antibodies
are described in Supplementary Table 1. Data was acquired on a FACS LSR II
or Canto II (BD Biosciences) and analysed using FlowJo (Treestar). Anti-Type 1
IFN-receptor antibody 5 μg/ml (mouse anti-human IFNα/βR chain 2) was used
for inhibition in vitro.
Molecular biology. All plasmids were generated using standard cloning, PCR and
fusion PCR techniques and based on pcDNA3.1 backbone (Invitrogen)28. For
in vitro transcription, a BAD-LAMP cDNA WT and Y276A were introduced in the
PGEM4Z vector (Promega) and transcribed in vitro by using mMessage T7
machine (Thermo Fisher) and poly adenylated with poly A tail kit (Thermo
Fisher). All procedure has been performed according manufacturer’s instructions
and described in Supplementary Table 2. 4 × 106 CAL-1 cell were transfected with
5 ug of mRNA using the Amaxa Cell line Kit V nucleofection kit according the
manufacturer’s instructions and described in Supplementary Table 2. CAL-1 were
activated 6 h post transfection for the indicated time and analysed. FlexiTube
siRNA targeting BAD-LAMP, UNC93B1, AP-3b1 and FlexiTube siRNA scramble
as control (QIAGEN) were used for RNA silencing experiments. 4 × 106 CAL-1 cell
were transfected with 1 ug of four siRNA mix using the Amaxa Cell line Kit V
nucleofection kit. CAL-1 were activated 24 h post transfection for the indicated
time and analysed. For quantitative PCR, total RNAs were extracted and puriﬁed
using the RNeasy Mini Kit (Qiagen). 100 ng to 1 µg of total RNA were subjected to
reverse transcription using SuperScript II. Each gene transcripts were quantiﬁed by
SYBR Green method with 7500Fast (Applied Biosystems). The relative amount of
each transcript was determined by normalising to internal housekeeping gene
expression. Oligonucleotides primers are described in Supplementary Table 3.
Statistical and quantitative analysis. Pearson coefﬁcient was calculated with
ImageJ using the JACOP plugging on the whole cell image. For each condition
between 25 and 50 cells were analysed. Data representing multiple experiments is
displayed as mean± s.d. UnPaired student’s t-test was used (Holm–Sidak method)
where indicated. Voxel gating were performed with the ‘Coloc’ tool from the
IMARIS software between 25 and 50 cells were analysed per conditions.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request.
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